Progress in the treatment of ocular graft-versus-host disease

VernacularTitle:眼部移植物抗宿主病治疗进展
Author: Suhua SUN ¹ ; Jing HONG
Author Information

1. 北京大学第三医院眼科，北京　100191
Keywords: Hematopoietic stem cell transplantation, allogeneic; Graft versus host disease, ocular; Therapy
From: Chinese Journal of Experimental Ophthalmology 2022;40(3):280-283
CountryChina
Language:Chinese
Abstract: Allogeneic hematopoietic stem cell transplantation is an effective therapy for the treatment of hematological benign and malignant tumors, but the occurrence of graft-versus-host disease (GVHD) will affect the whole organs and tissues, causing serious damages to the patient's body.This not only seriously affects the life quality of patients, but also increases the mortality of patients after transplantation.Ocular GVHD is a manifestation of ocular rejection, and 60%-90% of patients with chronic GVHD are accompanied by ocular GVHD, the manifestations of which are dry eye, conjunctivitis, keratitis, and so on.Severe ocular GVHD can cause vision loss.But there is no unified treatment standard at present.The commonly used treatments include artificial tears, autologous serum eye drops, topical glucocorticoid, topical immunosuppressive agents, punctal occlusion, and contact lens wearing.The treatment progress of ocular GVHD was reviewed in this article.